This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bernstein Liebhard LLP Announces Investigation Of Acquisition Of Abraxis BioScience Inc. By Celgene Corp.

Bernstein Liebhard LLP is investigating whether the Board of Directors of Abraxis BioScience Inc. (“Abraxis” or the “Company”) (NASDAQ: ABII) breached its fiduciary duty to its shareholders in agreeing to sell Abraxis to Celgene Corp. (“Celgene”) (NASDAQ: CELG).

Under the terms of the agreement, Abraxis shareholders will receive 0.2617 shares of Celgene and $58 in cash for each share they own, placing the total value of the transaction at approximately $2.9 billion. The Company’s revenue from Abraxane, a breast cancer treatment, jumped 25% in the first quarter 2010, to $87.9 million. The investigation is focused on the potential unfairness of the price to Abraxis shareholders and the process by which the Abraxis Board of Directors considered and approved the transaction.

If you are interested in discussing your rights as an Abraxis shareholder and/or have information relating to the matter, please contact U. Seth Ottensoser at (877) 779-1414 or Ottensoser@bernlieb.com.

Bernstein Liebhard has pursued hundreds of securities, consumer and shareholder rights cases and recovered almost $3 billion for its clients. It has been named to The National Law Journal’s “Plaintiffs’ Hot List” in each of the last seven years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
(877) 779-1414

www.bernlieb.com

ATTORNEY ADVERTISING. © 2010 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $130.25 -1.80%
FB $80.74 -1.40%
GOOG $553.67 -0.31%
TSLA $230.44 -0.48%
YHOO $44.34 -0.04%

Markets

DOW 18,110.14 +72.17 0.40%
S&P 500 2,114.76 +5.84 0.28%
NASDAQ 5,055.4220 -4.8240 -0.10%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs